Primary biliary cirrhosis Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Primary biliary cirrhosis Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Primary biliary cirrhosis is also known as primary biliary cholangitis is a disease which develops slowly and destroys the bile ducts in your liver. Bile aids in the digestion of cholesterol and helps in getting rid of the toxic and worn out red blood cells (RBCs) from the body. This is a chronic condition and is considered as an autoimmune disorder, however, the exact cause of the disease is unknown. Primary symptoms include dry eyes and mouth, fatigue and itchy skin. Complications of the disease involve liver failure, liver cancer, portal hypertension, splenomegaly which gives rise to an enlarged spleen, weak bones, vitamin deficiencies decrease in mental function and also increases the chance of giving rise to other diseases.
The report provides Primary biliary cirrhosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Shire, GENFIT SA, Virobay Inc., Albireo Pharma, Inc., Novimmune SA and Zydus Cadila among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration